176 related articles for article (PubMed ID: 37086459)
1. [Second and further lines treatment options for locally advanced or metastatic renal cell carcinoma].
Nagyiványi K; Géczi L
Magy Onkol; 2023 Apr; 67(1):61-72. PubMed ID: 37086459
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
3. Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era.
Schmidt AL; Tabakin AL; Singer EA; Choueiri TK; McKay RR
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-11. PubMed ID: 33793313
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.
Mantia CM; McDermott DF
Cancer; 2019 Dec; 125(23):4148-4157. PubMed ID: 31532565
[TBL] [Abstract][Full Text] [Related]
5. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
Loo V; Salgia M; Bergerot P; Philip EJ; Pal SK
Target Oncol; 2019 Dec; 14(6):639-645. PubMed ID: 31595385
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapeutic approaches in renal cell carcinoma.
Parekh H; Rini BI
Expert Rev Anticancer Ther; 2015; 15(11):1305-14. PubMed ID: 26376584
[TBL] [Abstract][Full Text] [Related]
7. [Tumor treatment of metastatic renal cell carcinoma : Comparison of immunotherapy with other drug options].
Uhlig A
Urologe A; 2019 Oct; 58(10):1208-1211. PubMed ID: 31471642
[No Abstract] [Full Text] [Related]
8. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.
Massari F; Nunno VD; Mollica V; Montironi R; Cheng L; Cimadamore A; Blanca A; Lopez-Beltran A
Immunotherapy; 2019 Dec; 11(17):1507-1521. PubMed ID: 31663411
[TBL] [Abstract][Full Text] [Related]
11. New insight into immune checkpoint inhibitors in the treatment of advanced renal cell carcinoma.
Wang H; Zhu Z; Zhang Y; Jiang T; Zhang M; Wang Z; Zhang Y; Zhao A; Su B
Sci China Life Sci; 2023 Apr; 66(4):875-878. PubMed ID: 36469217
[No Abstract] [Full Text] [Related]
12. [Metastatic renal cell carcinoma, back to the future].
Martins F; Berthold D
Rev Med Suisse; 2016 May; 12(519):994-8. PubMed ID: 27424427
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions.
Rambhia A; Patel RD; Okhawere KE; Korn TG; Badani KK
Urol Oncol; 2021 Oct; 39(10):664-677. PubMed ID: 34312081
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy in renal cell carcinoma.
Massari F; Di Nunno V; Ciccarese C; Graham J; Porta C; Comito F; Cubelli M; Iacovelli R; Heng DYC
Cancer Treat Rev; 2017 Nov; 60():152-157. PubMed ID: 28992528
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
16. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Jain RK; Gandhi S; George S
Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
[TBL] [Abstract][Full Text] [Related]
17. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
[TBL] [Abstract][Full Text] [Related]
18. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
Reed JP; Posadas EM; Figlin RA
Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
[TBL] [Abstract][Full Text] [Related]
19. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.
Bilen MA; Carlisle JW; Sonpavde G
Expert Opin Investig Drugs; 2018 Feb; 27(2):163-170. PubMed ID: 29323560
[TBL] [Abstract][Full Text] [Related]
20. What advances have been made in immune-therapy for renal cell carcinoma?
Verzoni E; Grassi P; Ratta R
Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
[No Abstract] [Full Text] [Related]
[Next] [New Search]
